117 related articles for article (PubMed ID: 37797658)
41. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
42. Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.
He J; Huang Y; Chen Y; Shi S; Ye L; Hu Y; Zhang J; Zeng Z
J Thorac Dis; 2016 May; 8(5):862-71. PubMed ID: 27162660
[TBL] [Abstract][Full Text] [Related]
43. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).
Reymen B; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Radiother Oncol; 2014 Mar; 110(3):482-7. PubMed ID: 24444527
[TBL] [Abstract][Full Text] [Related]
44. [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
Hu QY; Liu P; Wang L; Fu ZF
Ai Zheng; 2007 Apr; 26(4):394-7. PubMed ID: 17430659
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD; Hu C; Komaki RR; Masters GA; Blumenschein GR; Schild SE; Bogart JA; Forster KM; Magliocco AM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Koprowski CD; Olson MR; Meng J; Paulus R; Curran WJ; Choy H
J Clin Oncol; 2020 Mar; 38(7):706-714. PubMed ID: 31841363
[TBL] [Abstract][Full Text] [Related]
46. Long-Term Outcomes of Selected Patients with IIIA-N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection.
Fu F; Sun W; Bai J; Deng C; Zheng D; Li Y; Zhang Y; Chen H
Ann Surg Oncol; 2023 Dec; 30(13):8261-8270. PubMed ID: 37644250
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
[TBL] [Abstract][Full Text] [Related]
48. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Dang J; Li G; Zang S; Zhang S; Yao L
Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
[TBL] [Abstract][Full Text] [Related]
50. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
51. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
52. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D; Wei P; An G; Chen W
J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
[TBL] [Abstract][Full Text] [Related]
53. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
54. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
55. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
[TBL] [Abstract][Full Text] [Related]
56. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
57. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
58. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
Drake JA; Portnoy DC; Tauer K; Weksler B
Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
[TBL] [Abstract][Full Text] [Related]
59. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H
Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126
[TBL] [Abstract][Full Text] [Related]
60. Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.
Su L; Chen M; Su H; Dai Y; Chen S; Li J
BMC Cancer; 2019 Oct; 19(1):1023. PubMed ID: 31666026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
